A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumor

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (Monotherapy Dose Escalation, and Safety Expansion; Combination Dose Confirmation and Safety Expansion) and Phase 1b (Dose Expansion).

Key facts

Study ID

NCT06625593

Run by

BeOne Medicines

People needed

168

Starts

2024-12-09

Expected to finish

2026-12-31

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed advanced or metastatic solid tumors.
• Life expectancy of ≥ 3 months.
• Prior standard systemic therapy in the advanced or metastatic setting. Dose Escalation: Participants for whom further standard treatment is not available, not tolerated or determined not appropriate based on the investigator's judgment. Combo Dose Confirmation, Combo Safety Expansion, and Dose Expansion: Participants who have received at least 1 or 2 prior lines of systemic therapy, which included a fluoropyrimidine and/or a platinum in the advanced or metastatic setting
• Tumors with FGFR2b expression/ or FGFR2 gene amplification. Participants must provide agreement for collection of archival tissue or recently obtained fresh tumor biopsy for central evaluation of FGFR2b expression levels and other biomarker assessments.
• ≥ 1 measurable lesion per RECIST v1.1.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Adequate organ function as determined per protocol.

You may not qualify if…

• Prior exposure to topoisomerase I inhibitor (TOP1i)-based antibody-drug conjugate (ADC) therapies or FGFR2b-targeted ADC therapies.
• Active or chronic corneal disorder, history of corneal transplantation, corneal keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration, other active ocular conditions and any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.
• Spinal cord compression, or active leptomeningeal disease or uncontrolled, untreated brain metastasis.
• Systemic antitumor therapy (including targeted therapy and immunotherapy ≤ 14 days, ≤ 28 days for immuno- oncological antibody, ≤ 14 days or 5 half-lives [whichever is shorter] for chemotherapy, ADCs, or investigational therapy) before first dose of study drug(s).
• Toxicities due to prior therapy that have not recovered.
• Any malignancy ≤ 2 years before first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively.
• History of interstitial lung disease (ILD), noninfectious pneumonitis, oxygen saturation at rest < 92%, or requirement for supplemental oxygen at baseline.
• Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Where it is running

• Yale Cancer Center — New Haven, Connecticut, United States (enrolling)
• Usc Norris Comprehensive Cancer Center (Nccc) — Los Angeles, California, United States (enrolling)
• Md Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States (enrolling)
• University of Wisconsin — Madison, Wisconsin, United States (enrolling)
• Blacktown Cancer and Haematology Centre — Blacktown, New South Wales, Australia (enrolling)
• Liverpool Hospital — Liverpool, New South Wales, Australia (enrolling)
• Icon Cancer Centre South Brisbane — South Brisbane, Queensland, Australia (enrolling)
• Monash Health — Clayton, Victoria, Australia (enrolling)
• Cabrini Hospital Malvern — Malvern, Victoria, Australia (enrolling)
• The First Affiliated Hospital of Bengbu Medical University — Bengbu, Anhui, China (enrolling)
• Anhui Provincial Hospital — Hefei, Anhui, China (enrolling)
• The Second Hospital of Anhui Medical University — Hefei, Anhui, China (enrolling)
• Beijing Friendship Hospital, Capital Medical University — Beijing, Beijing Municipality, China (enrolling)
• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
• Fujian Medical University Union Hospital — Fuzhou, Fujian, China (enrolling)
• The First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China (enrolling)
• Zhongshan Hospital Xiamen University — Xiamen, Fujian, China (enrolling)
• Guangxi Medical University Cancer Hospital Wuxiang Branch — Nanning, Guangxi, China (enrolling)
• The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei, China (enrolling)
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China (enrolling)
• The First Affiliated Hospital of Henan University of Science and Technology — Luoyang, Henan, China (enrolling)
• The First Affiliated Hospital of Xinxiang Medical University — Xinxiang, Henan, China (enrolling)
• Henan Cancer Hospital — Zhengzhou, Henan, China (enrolling)
• Hubei Cancer Hospital — Wuhan, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.